Abstract
The use of bone morphogenetic proteins (BMP) as an adjunct to spinal fusion has increased since FDA approval in 2002. The incidence of postoperative complications with the use of BMP, though, reported in case series and larger IDE trials, is not well characterized after lumbar fusions.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
